Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
Sponsor: Brii Biosciences Limited
Summary
This Phase 2, randomized, double-blind study will evaluate the clinical efficacy and safety of the combination therapy of BRII-179, BRII-835, plus PEG-IFNα compared to PEG-IFNα in adult participants with chronic HBV infection without cirrhosis receiving neucloes(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.
Official title: A Phase 2 Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and Pegylated Interferon Alpha (PEG-IFNα) in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
250
Start Date
2024-10-31
Completion Date
2027-07
Last Updated
2025-05-23
Healthy Volunteers
No
Interventions
BRII-179
BRII-179 will be given via intramuscular injection
BRII-835 (VIR-2218)
BRII-835 will be given via subcutaneous injection
PEG-IFNα
PEG-IFNα will be given via subcutaneous injection
Placebo of BRII-179
Placebo of BRII-179 will be given via intramuscular injection
Placebo of BRII-835
Placebo of BRII-835 will be given via subcutaneous injection
Locations (14)
Investigative Site 86001
Beijing, Beijing Municipality, China
Investigative Site 86003
Beijing, Beijing Municipality, China
Investigative Site 86004
Beijing, Beijing Municipality, China
Investigative Site 86005
Beijing, Beijing Municipality, China
Investigative Site 86016
Beijing, Beijing Municipality, China
Investigative Site 86002
Guangzhou, Guangdong, China
Investigative Site 86013
Guangzhou, Guangdong, China
Investigative Site 86015
Shenzhen, Guangdong, China
Investigative Site 86006
Shanghai, Shanghai Municipality, China
Investigative Site 86007
Shanghai, Shanghai Municipality, China
Investigative Site 86010
Chengdu, Sichuan, China
Investigative Site 86011
Chengdu, Sichuan, China
Investigative Site 86012
Chengdu, Sichuan, China
Investigative Site 86009
Hangzhou, Zhejiang, China